Bridget E. Bunner

Array ( [id] => 20031991 [patent_doc_number] => 20250170213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => METHODS RELATED TO THE TREATMENT OF IGA NEPHROPATHY [patent_app_type] => utility [patent_app_number] => 19/054646 [patent_app_country] => US [patent_app_date] => 2025-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19054646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007485 [patent_doc_number] => 20250145707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/006997 [patent_app_country] => US [patent_app_date] => 2024-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19006997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19984034 [patent_doc_number] => 20250122256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => TNF-ALPHA VARIANT FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 18/942121 [patent_app_country] => US [patent_app_date] => 2024-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18942121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19984034 [patent_doc_number] => 20250122256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => TNF-ALPHA VARIANT FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 18/942121 [patent_app_country] => US [patent_app_date] => 2024-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18942121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19984034 [patent_doc_number] => 20250122256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => TNF-ALPHA VARIANT FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 18/942121 [patent_app_country] => US [patent_app_date] => 2024-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18942121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19768305 [patent_doc_number] => 20250049731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => DESIGNED ANTIBODY-BOUND NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 18/912238 [patent_app_country] => US [patent_app_date] => 2024-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19768305 [patent_doc_number] => 20250049731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => DESIGNED ANTIBODY-BOUND NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 18/912238 [patent_app_country] => US [patent_app_date] => 2024-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19768305 [patent_doc_number] => 20250049731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => DESIGNED ANTIBODY-BOUND NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 18/912238 [patent_app_country] => US [patent_app_date] => 2024-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691227 [patent_doc_number] => 20250009772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 18/883719 [patent_app_country] => US [patent_app_date] => 2024-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18883719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448956 [patent_doc_number] => 20240309086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/651002 [patent_app_country] => US [patent_app_date] => 2024-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18651002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300012 [patent_doc_number] => 20240228581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => TNFR2 Agonists with Improved Stability [patent_app_type] => utility [patent_app_number] => 18/619759 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18619759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675953 [patent_doc_number] => 12187803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Bispecific antibody that binds to CD116 and CD131 [patent_app_type] => utility [patent_app_number] => 18/587502 [patent_app_country] => US [patent_app_date] => 2024-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 28 [patent_no_of_words] => 69274 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18587502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19084116 [patent_doc_number] => 20240110917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/379036 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112800 [patent_doc_number] => 20240124550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => RECOMBINANT IMMUNE CELLS, METHODS OF MAKING, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/474781 [patent_app_country] => US [patent_app_date] => 2023-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18474781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096384 [patent_doc_number] => 20240115611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/470745 [patent_app_country] => US [patent_app_date] => 2023-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18470745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096384 [patent_doc_number] => 20240115611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/470745 [patent_app_country] => US [patent_app_date] => 2023-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18470745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902773 [patent_doc_number] => 20240018258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/458692 [patent_app_country] => US [patent_app_date] => 2023-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18458692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19641418 [patent_doc_number] => 20240415938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS) [patent_app_type] => utility [patent_app_number] => 18/695013 [patent_app_country] => US [patent_app_date] => 2023-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18695013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770884 [patent_doc_number] => 20230365686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/337875 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649521 [patent_doc_number] => 20230295337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 18/327456 [patent_app_country] => US [patent_app_date] => 2023-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18327456 [rel_patent_id] =>[rel_patent_doc_number] =>)